Sun Pharma looks to shine with tiny deals

Its subsidiary Taro's acquisition of Thallion Pharma is ninth acquisition since buying Ranbaxy

Abhineet Kumar  |  Mumbai 

Sun Pharmaceutical’s subsidiary, Taro, made a tiny acquisition of Thallion Pharmaceuticals for $1.7 million in Canada on March 17. It was the ninth acquisition by Sun Pharma and its subsidiaries in the previous two years since it made a $4.2-billion big-bang acquisition of Ranbaxy Laboratories in 2015. Till the acquisition of Ranbaxy, the company had made only seven acquisitions in 18 years, including Taro Pharma in Israel in 2010. The first was in 1997, when it acquired US-based Caraco for $37.5 million. This gave the Dilip Shanghvi-promoted company an entry into the ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?
LOGIN

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

Sun Pharma looks to shine with tiny deals

Its subsidiary Taro's acquisition of Thallion Pharma is ninth acquisition since buying Ranbaxy

Mumbai, 27 MarchSun Pharmaceutical's subsidiary, Taro, made a tiny acquisition of Thallion Pharmaceuticals for $1.7 million in Canada on March 17. It was the ninth acquisition by Sun Pharma and its subsidiaries in the previous two years since it made a $4.2-billion big-bang acquisition of Ranbaxy Laboratories in 2015.Till the acquisition of Ranbaxy, the company had made only seven acquisition in 18 years, including Taro Pharma in Israel in 2010. The first was in 1997, when it acquired US-based Caraco for $37.5 million. This gave the Dilip Shanghvi-promoted company an entry into the lucrative US markets."With the Ranbaxy acquisition, Sun Pharma got a wide marketing platform," says Ajay Garg, managing director, Equirus Capital, a home-grown investment banking firm advising on pharma mergers and acquisitions. "Following this, they have adopted a string of pearls strategy by largely acquiring specialty product companies which they can milk well across the marketing platform."Thallion ... Sun Pharmaceutical’s subsidiary, Taro, made a tiny acquisition of Thallion Pharmaceuticals for $1.7 million in Canada on March 17. It was the ninth acquisition by Sun Pharma and its subsidiaries in the previous two years since it made a $4.2-billion big-bang acquisition of Ranbaxy Laboratories in 2015. Till the acquisition of Ranbaxy, the company had made only seven acquisitions in 18 years, including Taro Pharma in Israel in 2010. The first was in 1997, when it acquired US-based Caraco for $37.5 million. This gave the Dilip Shanghvi-promoted company an entry into the ... image
Business Standard
177 22